ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Advanced Biomaterial Delivery of Hypoxia-Conditioned Extracellular Vesicles (EVs) as a Therapeutic Platform for Traumatic Brain Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Potential and Prospects of Hydrogel Applications in Traumatic Brain Injury Treatment.Current issues in molecular biology · 2026Review
- From fragmented neurotechnologies to closed-loop brain health systems: integrating artificial intelligence, digital health, digital twins, and advanced materials for brain disorders.Frontiers in bioengineering and biotechnology · 2026Article
- Advanced Biomaterial Delivery of Hypoxia-Conditioned Extracellular Vesicles (EVs) as a Therapeutic Platform for Traumatic Brain Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Traumatic Brain Injury (TBI) is a common and debilitating injury, causing long-lasting neurological deficits. Current therapeies for recovery remain inadequate, undersing the urgent need for innovative interventions. In this study, a novel therapeutic approach is introduced that delivers extracellular vesicles (EVs) derived from human-induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) with a gelatin-based injectable bioorthogonal hydrogel (BIOGEL). The hiPSC-NPCs are conditioned with deferoxamine (DFO) to simulate hypoxia, resulting in EVs enriched with neurotrophic and angiogenic factors critical for neural repair. The biomimetic mechanical properties of BIOGEL, similar to those of native brain tissue, contribute to sustained EV delivery and promote neural regeneration. BIOGEL with hypoxia-conditioned EVs showed significant tissue regeneration in vivo using a rat model of TBI. Our nanomaterial platform reduced cortical lesions, improved neurological and motor recovery, enhanced hippocampal neurogenesis and myelination, and reduced neuroinflammation, demonstrating strong therapeutic potential for neural repair. In summary, this study demonstrated proof-of-concept for a multifaceted therapeutic platform that simultaneously targets key pathological features of TBI, providing a scalable and clinically translatable approach to effective neural tissue regeneration. The synergistic combination of hypoxia-conditioned EVs and biomaterial delivery offers a promising strategy for advancing regenerative medicine techniques for neural repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.